Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2019-01-17
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Platelet Population Changes Under Circulatory Support With ECMO
NCT07334457
Interest in Evaluating Primary Hemostasis in Patients With Veno-venous Extracorporeal Membrane Oxygenation (ECMO)
NCT03248596
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
NCT00780767
Can Blood Panels Provide Early Warning of Bleeding in Patients on ECMO?
NCT04478136
Surgical Pulmonary Embolectomy Versus Catheter-directed Thrombolysis in the Treatment of Pulmonary Embolism: A Non-inferiority Study
NCT03218410
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be divided into three groups:
A: patients on V-A ECMO without P2Y12 inhibitors B patients on V-A ECMO with P2Y12 inhibitors with administration of P2Y12 inhibitor at the time of ECMO insertion C: patients on V-A ECMO already recieving P2Y12 inhibitors at the time of ECMO insertion.
Blood samples will be taken prior to and at 2, 4, 12, 22, 48, 72 after ECMO insertion and after removal of an ECMO. VerifyNow System will be used to measure platelet agregation (PRU test).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
V-A ECMO without P2Y12 inhibitors
control group
P2Y12 Platelet Aggregation Inhibitor
Verify now PRU test
V-A ECMO with P2Y12 inhibitor at the time of ECMO
observational group 1
P2Y12 Platelet Aggregation Inhibitor
Verify now PRU test
V-A ECMO already recieving P2Y12 inhibitors
observational group 2
P2Y12 Platelet Aggregation Inhibitor
Verify now PRU test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
P2Y12 Platelet Aggregation Inhibitor
Verify now PRU test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* thrombocitopenic patents (\< 50\*109/L),
* patients treated with eptifibatide ali bivalirudin
* patients younger than 18 years
* pregnant patients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marko Noc
MD PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UMC Ljubljana
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KOIIM-UM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.